Abstract:Abstract The confirmation of target engagement for candidate drugs is a fundamental requisite in drug discovery. A significant portion of projects fail to reach the clinic due to lack of efficacy or failure to show lead candidates interacting with the intended target in a more complex environment. The utility of using the CETSA® (CEllular Thermal Shift Assay) technology to measure target engagement in intact cells is increasingly exploited in high throughput screening, where examples demonstrate low false positive rates in screens of up to 500K compounds. The p53 tumor suppressor protein, a crucial guardian against cancer, functions as a transcription factor that mediates cancer suppression by regulating genes involved in a wide range of cellular processes such as DNA repair, cell cycle and apoptosis. Unfortunately, frequent mutations in the TP53 gene hinder p53's tumor suppressor role in human cancers, thus designating it as a promising target for anticancer therapy. However, attempts to restore p53 function for therapeutic purposes have not yet advanced to clinical approval, highlighting the complexities in leveraging p53 for cancer treatment. Its undruggable nature, attributed to the absence of accessible deep pockets, lack of enzymatic activity, and its intracellular location, further complicates targeted interventions with both low and high molecular weight drugs. Here, we demonstrate the analysis of a high-throughput plate based CETSA® HT screen on the challenging target p53, performed using AlphaLISA® SureFire® UltraTM technology and our newly developed high-throughput screening platform. Hits identified from this screen are privileged from the onset by binding to the target in a physiologically relevant cellular matrix and in a binding-mode agnostic way. This is in contrast to traditional screening methods targeting activity or in vitro interaction where cellular activity is addressed in later stages. This assay cascade highlights a rapid target-to-hit lead generation strategy placing the emphasis on finding chemical matter that interacts with endogenous target in living cells first, followed by analysis of hit material activity. The ‘shortcut’ to chemical matter active in living cells represents significant potential cost savings in comparison to assay development time on recombinantly produced proteins and/or modified cell lines for traditional HTS screening approaches that still rely on target engagement assessment downstream. Citation Format: Merve Kacal, Tomas Friman, Laurence Arnold, Victoria Brehmer, Daniel Martinez Molina, Stina Lundgren. CETSA HT: Employing rapid high-throughput target engagement technology in primary screening of P53 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3097.

Affinity Ultrafiltration of DNA Topoisomerases-Targeted Compounds Determined with HPLC/ESI-MS for Drug Candidate Screening

New Approach for Screening Anti-Tumor Compounds

Immobilized magnetic beads-based multi-target affinity selection coupled with HPLC-MS for screening active compounds from traditional Chinese medicine and natural products.

A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs.

An Analysis Method for Simultaneous Screening of Deoxyribonucleic Acid-Binding Active Compounds and Investigating Their Mechanisms by Ultra-Fast Liquid Chromatography Tandem Mass Spectrometry Coupled with Fluorescence Detection Technology.

An integrative approach for the isolation, screening and analysis of antitumor agents by liquid chromatography combined with mass spectrometry.

Systematic analysis of natural topoisomerase I inhibitors from Forsythiae Fructus by ultrafiltration-UPLC-ESI-MS/MS, pharmacophore modelling, and molecular dynamics simulation

Development of target-based cell membrane affinity ultrafiltration technology for a simplified approach to discovering potential bioactive compounds in natural products

Probing the Mechanism of Action of Potential Anticancer Agents at a Molecular Level Using Electrospray Ionisation Fourier Transform Ion Cyclotron Resonance Mass Spectrometry

Rapid Screening of Multi-Target Antitumor Drugs by Nonimmobilized Tumor Cells/tissues Capillary Electrophoresis

High-throughput screening of triplex DNA binders from complicated samples by 96-well pate format in conjunction with peak area-fading UHPLC-Orbitrap MS

Quantitative Mass Spectrometry Combined with Separation and Enrichment of Phosphopeptides by Titania Coated Magnetic Mesoporous Silica Microspheres for Screening of Protein Kinase Inhibitors.

Computational screening and molecular docking of compounds from Traditional Chinese Medicine (TCM) by targeting DNA topoisomerase I to design potential anticancer drugs

Microfluidic-Based G-Quadruplex Ligand Displacement Assay for Alkaloid Anticancer Drug Screening

Screening of high-efficiency and low-toxicity antitumor active components in Macleaya cordata seeds based on the competitive effect of drugs on double targets by a new laminar flow chip

Immobilized Magnetic Beads Based Multi-Target Affinity Selection Coupled with High Performance Liquid Chromatography-Mass Spectrometry for Screening Anti-Diabetic Compounds from a Chinese Medicine "Tang-Zhi-qing".

Using Affinity Selection To Screen New Drugs In Combinatorial Libraries

Discovery of selective HDAC6 inhibitors based on a multi-layer virtual screening strategy

Abstract 3097: CETSA HT: Employing rapid high-throughput target engagement technology in primary screening of P53

Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors

Recent advances in screening active components from natural products based on bioaffinity techniques